KAZIA THERAPEUTICS LIMITED

Maravai Lifesciences Holdings, Inc. (MRVI) stock rose 5.09% to $7.84 with a trading volume of 531,902 shares. The company reported revenue of $73.40 million, a net loss of $7.59 million, and an EPS of -$0.06. 73% of analysts recommend buying MRVI, with no sell recommendations. The biotech industry declined 0.20%, but stocks like Neurogene Inc. and Tenaya Therapeutics, Inc. gained. Maravai specializes in nucleic acid production, biologics safety testing, and protein detection.

Kazia Therapeutics reported a 67% partial response rate with 45mg paxalisib and radiotherapy in a Phase I study for solid tumor brain metastases with PI3K pathway mutations, presented at ASTRO 2024. Over two-thirds of patients at maximum tolerated dose achieved intracranial response, suggesting paxalisib's potential in overcoming tumor radioresistance.

Kazia Therapeutics (NASDAQ: KZIA) focuses on oncology, with lead drug paxalisib for glioblastoma. Other drugs include EVT801 and Cantrixil. Strategic partnerships and direct offerings fund R&D. Compliance with Nasdaq's Minimum Bid Price Requirement is maintained.

Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.